TD Ameritrade Holding Corporation (AMTD) didn't experience a spectacular start to its new fiscal year. The broker, which competes with Charles Schwab (SCHW) and E*Trade Financial Corporation (ETFC), was hampered by a decline in trading activities.

According to the press release, revenues increased a modest 2% from the year-ago period. On a sequential basis, the top line actually contracted. Net income decreased 26% to 23 cents per share. Earnings.com indicates an expectation of 26 cents per share. Margins and profitability metrics unfortunately were down across the board.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Adobe Systems Inc. (ADBE) shares rose after lower Q4 earnings and revenue beat analysts' expectations.
• Best Buy Inc. (BBY) shares sold off despite better-than-expected Q3 results due to the lower gross margin.
• Charles Schwab Corp. (SCHW) warned that Q4 earnings would come in lower than the Street view
• Discover Financial Services (DFS) shares were up after it reported better-than-expected Q4 earnings.
• First Solar Inc. (FSLR) offered a solid 2010 outlook but the consensus EPS estimate is high in the range.
• General Mills Inc. (GIS) strong Q2 results included better-than-expected earnings and a rosy outlook.

Charles Schwab (SCHW - option chain) stock is trading lower today after the company said it expects fourth-quarter earnings will be 2 to 4 cents a share lower than the 17-cent profit reported for the third quarter. Analysts have forecast a profit of 17 cents per share. If you think this stock won't be rising too far in the coming months, then it could be a good time to look at a bearish hedged play on SCHW.

This morning, SCHW opened at $18.04. So far today the stock has hit a high of $18.35 and a low of $17.74. As of 12:00, SCHW is trading at $17.89, down 54 cents(-2.9%). The chart for SCHW looks bearish and S&P gives SCHW a negative 2 STARS (out of 5) sell ranking.

Look before you leap! All year long rumors have been swirling around that E*TRADE (ETFC) was on the auction block being prepared for an acquisition by a bigger fish interested in its customers and superior trading platform. I have not used E-TRADE so I do not have first hand experience. However, this has been acknowledged broadly and I have received very positive comments from regular users when I have written about it.

The leading suitor seems to be TD AmeriTrade Holding (AMTD), with Charles Schwab Corp (SCHW) mentioned as perhaps having similar but less conspicuous interest. For Schwab it may be as much about keeping E-TRADE out of a competitors hands as chasing the business.

E*Trade (NASDAQ: ETFC) is a well-known brand in the broker space. It competes vigorously with the other giants, TD Ameritrade (NASDAQ: AMTD) and Charles Schwab (NASDAQ: SCHW). To be honest, if I were looking for investment ideas in this sector, I would probably begin my search with the latter two. It's difficult to put E*Trade on the list. The company got in trouble during the financial crisis because it was exposed to the mortgage industry. It has now become, in my opinion, a speculative play on a return to glory.

The latest earnings report shows what I'm talking about. For the third quarter, E*Trade lost, on a GAAP basis, 66 cents per share from continuing operations, wider than the year-ago loss of 60 cents per share from continuing operations. After adjusting for an item related to debt extinguishment, the current red ink is equal to 5 cents per share.

Analyst upgrades:

• Citigroup upgraded Procter & Gamble (NYSE:PG) to Buy from Hold after meeting with management as it believes a more aggressive strategy will lead to the company regaining market share. Citi raised its target on shares to $66 from $54.
  
• Piper Jaffray upgraded Allscripts (NASDAQ:MDRX) to Overweight from Neutral after learning the company signed a large contract with North Shore Long Island Jewish Hospital. Piper now sees upside to estimates and raised its target on shares to $22.50 from $14.
  
• UBS upgraded Amedisys (NASDAQ:AMED) to Buy from Neutral following a review of the Senate Finance Committee's healthcare proposal, which they view as "benign." The firm raised its target to $57 from $46.
• Daimler (NYSE:DAI) was upgraded to Outperform from Market Perform at Bernstein.
  
• Boston Private (NASDAQ:BPFH) was upgraded to Outperform from Market Perform at Keefe Bruyette.
  
• E-Trade (NASDAQ:ETFC) was upgraded to Buy from Neutral at Goldman.

Brokerage house Charles Schwab & Co. (NASDAQ: SCHW) is facing the wrath of New York Attorney General Andrew Cuomo. The state's top attorney sent a letter to Schwab last Friday, warning that he plans to sue the firm for civil fraud in relation to its marketing and sales of auction-rate securities (ARS). Cuomo added that he is open to a possible settlement, although Schwab must be willing to repurchase ARS from its investors who are still holding them.

In response, Schwab is defending itself. "The Attorney General's allegations are without merit," stated the brokerage firm. "They unfairly lay blame on our company for an illiquid market and improper behavior by the large Wall Street firms."

Today was one of those days that was going to start out soft, but a key analyst upgrade saved the day. There was actually no early economic data, and traders are putting on their pre-earnings trades. Here is a quick look at the earnings previews for this week's key technology stocks and for this week's key financial stocks.

Here were today's unofficial closing bell levels:

Dow 8,313.92 +167.40 (2.05%)
S&P 500 901.05 +21.92 (2.49%)
Nasdaq 1,793.21 +37.18 (2.12%)

Top Analyst Calls

My investment world leads me to deal with many brokers and I am constantly amazed at the bad advice that is so prevalent in the financial industry. I think many brokerage houses remain conflicted, try as they might to be otherwise.

Here is the latest example to reach my doorstep. We have personal assets with Charles Schwab (NASDAQ: SCHW) and they publish an in-house magazine for their clients called "onInvesting". In the summer 2009 issue listed under the heading of "Expert Insight" there is an article titled "How Sector Investing Can Work for You". I could not find a link to the story online. It is written by Brad Sorenson, CFA, director, Sector Analysis, Schwab Center for Financial Research.

I know, I know. You look at the recent performace of E*Trade's (NASDAQ: ETFC) shares and you say to yourself, man, I've got to play this stock and make some return! Sure, E*Trade shares have doubled since the first of the year. But then the earnings hit the fan, my trading friends, and that double suddenly disappeared.

The brokerage reported a Q1 loss that was wider than the year-ago number. E*Trade lost 41 cents per share versus a loss of 20 cents per share in 2008. According to this source, that was a penny worse than what Wall Street was bracing itself for.

TheStreet.com's Jim Cramer is seeing signs of a coming boom, but he's still being cautious here.

If you had to define the early cycle, if you had to outline what stocks should be soaring coming out of a recession into a boom and which ones should be faltering, you would have to say the action in this market in the last month is the quintessential behavioral pattern.

What are the components of the early cycle? First, it's the homebuilders. As is typical coming out of a recession, the stocks precede the bottom of housing. That's exactly what's happening with the lowest permits and highest affordability and best mortgage rates and massive inventory. Everywhere, except on Wall Street reporting, the bottom is bursting out. When you read the lead story in the Sunday Philadelphia Inquirer, and it is all about the thousands of prospective homebuyers heading south to pick up condos and homes for half of what they were worth two years ago -- or even less -- and you know that virtually no one has broken ground in the Sunshine State in a year, you can bet that the bottom's actually behind us. This housing market has wiped out all but the most stable private builders and even the public ones are merging as we know from Pulte (NYSE: PHM) (Cramer's Take) and Centex (NYSE: CTX) (Cramer's Take). So, in the next cycle, you can see some profitability developing year over year even though the new homes don't have much margin because the foreclosed homes next door are going for a song. And don't believe this won't change the dynamic of future foreclosures. In most areas, rent is higher than the interest on mortgages, so you will find that second or third job needed to stay in your home. The incentive structure's radically different than a year ago.

Here are some highlights from this past week's earnings coverage from BloggingStocks:

• Abbott Laboratories (NYSE: ABT) Q1 profit edged past expectations despite lower sales of Humira.
• AMR Corp. (NYSE: AMR) posted a smaller-than-expected Q1 loss, sending shares sharply higher.
• Baxter International Inc. (NYSE: BAX) reported better-than-expected Q1 earnings, sending share higher.
• BP (NYSE: BP) and other oil companies were downgraded due to higher environmental costs.
• Charles Schwab Corp. (NASDAQ: SCHW) Q1 earnings declined but still topped analysts' expectations.
• Chevron Corp. (NYSE: CVX) said Q1 earnings would be lower due to a weaker dollar and lower oil prices.

On Wednesday, Charles Schwab Corp. (NASDAQ: SCHW) reported that its lower first-quarter earnings easily topped analysts' estimates, and Abbott Laboratories (NYSE: ABT) said its higher first-quarter profit edged past Wall Street expectations. Shares of Schwab surged while those of Abbott Labs fell Wednesday.

San Francisco-based brokerage and investment manager Charles Schwab said it earned $218 million, or 19 cents per share, for the quarter, as compared to $305 million, or 26 cents per share, in the same period of the previous year. Total revenue fell 15% year over year to $1.11 billion.

Analyst upgrades:

• Jefferies upgraded Abiomed (NASDAQ: ABMD) to Hold from Underperform on valuation as it believes concerns over the company's Impella heart pump are priced in at current levels. The firm lowered its target price to $7 from $8.
  
• Suntrust upgraded Somanetics (NASDAQ: SMTS) to Neutral from Reduce. The firm believes most of the risk is out of Somanetics shares and that the Q1 report could be a positive catalyst.
  
• Banc of America/Merrill upgraded shares of Telecom Italia (NYSE: TI) to Buy from Neutral on valuation and believes the company's revenue trends are improving.
• China Petroleum & Chemical (NYSE: SNP) was raised to Buy from Neutral at UBS.
• Hexcel (NYSE: HXL) and Johnson Controls (NYSE: JCI) were upgraded to Buy from Neutral at Goldman.

In his Stellar Stocks Alert, newsletter advisor Richard Schmidt sees long-term opportunity in select brokerage stocks. Here, he looks at Charles Schwab (NASDAQ: SCHW) and E*Trade (NASDAQ: ETFC).

"Some of the strongest financials in the world have lost 60%, 70%, even up to 90% or more of their value in the last year. Shares of Charles Schwab have come down too. But the stock has lost less than 50%, at its worst.

"Most of that has come since October. We had hoped the stock would bottom. But the stock continued to drop through support, meaning the downtrend is still in place. We may eventually see it go down by more than 50%.